An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA...
Main Authors: | Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-021-01408-9 |
Similar Items
-
CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells
by: Rachel L. Mintz, et al.
Published: (2020-01-01) -
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
by: Monika Toma, et al.
Published: (2019-10-01) -
Advances in using PARP inhibitors to treat cancer
by: Kummar Shivaani, et al.
Published: (2012-03-01) -
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
by: Nicola J Curtin
Published: (2020-02-01) -
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
by: Erik H. Knelson, et al.
Published: (2021-02-01)